Table 1.

Indications for PCSK9i use in Brazil, according to the Brazilian Guideline on Dyslipidemia.²⁴

Patients at high risk of a CV event
On treatment with statins at the highest tolerated dose
Statin or statin + ezetimibe therapy
Statin-intolerant or has not met recommended LDL or non-HDL goals↓
Evolocumab (Repatha™)	Alirocumab (Praluent®)
140 mg by subcutaneous injection every 2 weeks or 420 mg once a month Both doses reduce LDL by approximately 60%.25	75 mg or 150 mg by subcutaneous injection every 2 weeks The 75-mg and 150-mg doses are associated with average LDL reductions of 45% and 60%, respectively.25